Moderna is trading 4.6% higher at $146.80, with no clear company-specific catalyst identified for the September 1, 2026 move.
- The company announced upcoming investor-conference appearances, but the disclosure does not explain the intraday gain.
- Attention remains on the $2.6 billion convertible-note offering, scheduled to close September 1.
- Potential dilution makes the offering an unlikely direct bullish catalyst.